| Approach |
Appropriate population |
Description |
Esmya®
(Selective Progesterone Receptor Modulator, SPRM)
EU Market only |
Young or premenopausal women |
- Orally administered
- Treats multifactorial symptoms of uterine fibroids such as bleeding, amenorrhea, pain and fibroids size
- Rapid and sustained reduction in heavy bleeding
- Continuous reduction of fibroid size
- Repeated 3-months treatment courses that need to be separated by off-drug interval
|
| GnRH1 agonists |
Preoperative therapy in young or premenopausal women |
- Temporary treatment (3 to 6 months), fibroid re-growth on cessation
- Flare effect during the first month
- Route of administration: Injections
- Adverse effects including loss of bone mineral density and menopausal symptoms
|
| Pharmacological therapies used for treatment of Heavy Menstrual Bleeding (including LNG-IUS2, COC3, Oral progestogen, NSAIDs4 and tranexamic acid) |
Young or premenopausal women |
- Focused mainly on bleeding and /or pain. Limited or no effect on fibroid size
- LNG-IUS are contra-indicated in women with distorted uterus
|
1 GnRH: Gonadotrophin releasing hormone
2 LNG-IUS: Levonorgesteral-releasing intrauterine system
3 COC: Combined oral contraceptive pill
4 NSAID: Non-steroidal anti-inflammatory drug
